The Full Wiki

More info on Pardoprunox

Pardoprunox: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Pardoprunox
Systematic (IUPAC) name
7-(4-methylpiperazin-1-yl)-3H-1,3-benzoxazol-2-one
Identifiers
CAS number 269718-84-5
ATC code none
PubChem 6918524
ChemSpider 5293721
Chemical data
Formula C12H15N3O2 
Mol. mass 269.73 g/mol
SMILES eMolecules & PubChem
Therapeutic considerations
Pregnancy cat.  ?
Legal status Uncontrolled
Routes Oral

Pardoprunox (SLV-308) is an antiparkinsonian drug currently under development by Solvay for the treatment of Parkinson's disease and as of March 2010 is in Phase III clinical trials.[1][2][3] It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned.[1]

Pardoprunox acts as a D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT1A receptor (pKi = 8.5) full agonist (IA = 100%).[1][4] It also binds to D4 (pKi = 7.8), α1-adrenergic (pKi = 7.8), α2-adrenergic (pKi = 7.4), and 5-HT7 receptors (pKi = 7.2) with lower affinity.[1][4] Relative to other dopaminergic antiparkinsonian agents, pardoprunox is thought to have significantly less of a propensity for inducing certain side effects like dyskinesia and psychosis.[4][5]

See also

References

  1. ^ a b c d Wolf WA (July 2003). "SLV-308. Solvay". Current Opinion in Investigational Drugs (London, England : 2000) 4 (7): 878–82. PMID 14619412. 
  2. ^ "Search of: pardoprunox - List Results - ClinicalTrials.gov". http://clinicaltrials.gov/ct2/results?term=pardoprunox. 
  3. ^ Bronzova J, Sampaio C, Hauser RA, et al. (March 2010). "Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease". Movement Disorders : Official Journal of the Movement Disorder Society. doi:10.1002/mds.22948. PMID 20198713. http://dx.doi.org/10.1002/mds.22948. 
  4. ^ a b c Glennon JC, Van Scharrenburg G, Ronken E, et al. (December 2006). "In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist"]. Synapse (New York, N.Y.) 60 (8): 599–608. doi:10.1002/syn.20330. PMID 17001660. http://dx.doi.org/10.1002/syn.20330. 
  5. ^ Gottwald MD, Aminoff MJ (July 2008). "New frontiers in the pharmacological management of Parkinson's disease". Drugs of Today (Barcelona, Spain : 1998) 44 (7): 531–45. doi:10.1358/dot.2008.44.7.1217105. PMID 18806903. http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summaryn_pr?p_JournalId=4&p_RefId=1217105. 

Further reading








Got something to say? Make a comment.
Your name
Your email address
Message